Recursion Pharmaceuticals Inc (RXRX) - News Archive

Revolutionizing Biomolecular Research: MIT and Recursion Unveil Boltz-2 The Future of AI in Predicting Binding Affinity In a notable advancement within the realm of computational biology, researchers at the Massachusett...

Recursion Pharmaceuticals to Attend Upcoming Investor Conferences Amidst Recent Stock StrugglesSalt Lake City, May 6, 2025 Recursion Pharmaceuticals Inc. (Nasdaq: RXRX), a pioneering TechBio company focused on decoding...

In the ever-evolving landscape of oncology, where the fight against cancer intensifies day by day, Recursion Pharmaceuticals, a beacon in the TechBio industry, recently emerged as a frontrunner with its groundbreaking a...

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a pioneering TechBio company known for its innovative approaches to drug discovery, has recently announced the approval of a substantial grant of inducement restricted sto...

Promising Phase 1 Data Unveils REC-617: A Potential Game-Changer in CDK7 Inhibition for Solid TumorsOn December 9, 2024, Recursion Pharmaceuticals Inc. marked a significant milestone in oncology research with the interi...

Recursion and Exscientia Unite to Forge a New Era in AI-Driven Drug Discovery SALT LAKE CITY, Nov. 20, 2024 — In a landmark move set to reshape the biotechnology landscape, the expected business combination between Recu...

Update Call Scheduled for November 20th: A New Dawn in Drug DiscoveryAs the clock ticks down to the anticipated update call scheduled for November 20th at 7:30 a.m. Eastern, investors and stakeholders are poised to glea...

Advancements in Drug Discovery and Microscopy Data: Recursion Pharmaceuticals Sets New StandardsIn an era where innovation and technological advancements are vital to the pharmaceutical industry, Recursion Pharmaceutica...

:Recursion Pharmaceuticals, a clinical-stage technology-driven drug discovery company, announced key advancements in its drug development pipeline and corporate partnerships. Notably, the U.S. Food and Drug Administrati...

Cerebral Cavernous Malformation (CCM) is a vascular disorder characterized by the presence of abnormal blood vessels in the brain, leading to symptoms such as seizures, headaches, and neurological deficits. The manageme...

The Evolution of Drug Discovery The pharmaceutical landscape is witnessing a significant transformation, underpinned by innovative technologies and strategic collaborations. Recent agreements and developments involving...

Recursion Pharmaceuticals Raises $200 Million in Public Offering to Advance Drug Discovery TechnologySalt Lake City-based TechBio company, Recursion Pharmaceuticals, Inc. (Recursion), recently announced the pricing of i...

The BioPharm Industry Embraces Technological Advancements: Recursion Pharmaceuticals Announces Proposed Offering and Completion of BioHive-2, the Largest SupercomputerRecursion Pharmaceuticals, Inc. (Recursion), a pione...

Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download DayRecursion, a leading clinical stage TechBio company focused on decoding biology to industrialize drug di...

CRISPR Gene Editing: Revealing New Complexities and Unveiling Advanced Solutions By The promise of CRISPR-Cas9 gene editing has been nothing short of revolutionary, vowing to transform medicine, agriculture, and even th...

Dr. Robert Hershberg Named Chair of Recursion Board of Directors: A New Chapter in LeadershipRecursion, a technology-enabled biotechnology company, has proudly announced the appointment of Dr. Robert Hershberg, M.D., Ph...

The breakthrough of intelligent machines and supercomputing has taken an exponential leap in the pharmaceutical industry. Recursion, an innovative interdisciplinary team working at the intersection of therapeutic develo...

In a strategic move to further establish its dominance in the field of TechBio, Recursion Pharmaceuticals has announced plans to open a new office in London s vibrant Kings Cross neighborhood. Alongside this exciting de...

Recursion Unveils Groundbreaking Drug Discovery Software at J.P. Morgan Healthcare ConferenceAt the highly anticipated J.P. Morgan Healthcare Conference, Recursion made waves by introducing its innovative LOWE software....

In an exciting revelation, Recursion Pharmaceuticals has introduced a groundbreaking chemical entity for combating fibrotic diseases in its late-stage discovery pipeline. Alongside this significant milestone, the compan...